Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 15, 2026, 2:25 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 159 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Prostate Cancer Metastatic to Bone Clear all
Completed Early Phase 1 Interventional

Pharmacodynamic Study of Radium-223 in Men With Bone Metastatic Castration-Resistant Prostate Cancer

NCT02204943
View directory record Official record
Conditions
Bone Metastatic Castration-Resistant Prostate Cancer
Interventions
Biomarker analysis, Administration of radium-223
Device · Drug
Lead sponsor
Duke University
Other
Eligibility
18 Years and older · Male only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 7, 2018 · Synced Sep 15, 2026, 2:25 AM EDT
Terminated Phase 2 Interventional Results available

Selinexor in Treating Patients With Abiraterone Acetate and/or Enzalutamide Refractory Metastatic Castration-Resistant Prostate Cancer

NCT02215161
View directory record Official record
Conditions
Castration Levels of Testosterone, Hormone-Resistant Prostate Cancer, Metastatic Prostate Carcinoma in the Soft Tissue, Prostate Carcinoma Metastatic in the Bone, PSA Progression, Stage IV Prostate Adenocarcinoma AJCC v7
Interventions
Selinexor
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older · Male only
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jun 25, 2018 · Synced Sep 15, 2026, 2:25 AM EDT
Completed Phase 2 Interventional Results available

Study to Evaluate the Safety and Effects AZD0530 on Prostate and Breast Cancer Subjects With Metastatic Bone Disease

NCT00558272
View directory record Official record
Conditions
Breast Cancer, Prostate Cancer, Bone Neoplasms
Interventions
AZD0530, Zoledronic Acid
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
139 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
9
States / cities
Pleasant Hill, California • Sacramento, California • Middlebury, Connecticut + 6 more
Source: ClinicalTrials.gov public record
Updated May 26, 2013 · Synced Sep 15, 2026, 2:25 AM EDT
Completed Phase 4 Interventional

Open-label Trial on the Effect of I.V. Zoledronic Acid 4 mg on Bone Density in Hormone Sensitive Prostate Cancer Patients With Bone Metastasis

NCT00035997
View directory record Official record
Conditions
Prostate Cancer
Interventions
Zometa
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older · Male only
Enrollment
261 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2004
U.S. locations
56
States / cities
Birmingham, Alabama • Anchorage, Alaska • Anaheim, California + 50 more
Source: ClinicalTrials.gov public record
Updated Nov 22, 2009 · Synced Sep 15, 2026, 2:25 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Cabazitaxel With or Without Carboplatin in Treating Patients With Previously Treated Metastatic Castration-Resistant Prostate Cancer

NCT01505868
View directory record Official record
Conditions
Castration Levels of Testosterone, Castration-Resistant Prostate Carcinoma, Lymphadenopathy, Metastatic Prostate Carcinoma, Prostate Adenocarcinoma, Prostate Carcinoma Metastatic in the Bone, Prostate Small Cell Carcinoma
Interventions
Cabazitaxel, Carboplatin, Laboratory Biomarker Analysis
Drug · Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older · Male only
Enrollment
170 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2019
U.S. locations
2
States / cities
Detroit, Michigan • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 29, 2021 · Synced Sep 15, 2026, 2:25 AM EDT
Completed Not applicable Interventional

Effect of Androgen Suppression on Bone Loss in Patients With or Without Bone Metastases Secondary to Prostate Cancer

NCT00003903
View directory record Official record
Conditions
Osteoporosis, Prostate Cancer
Interventions
management of therapy complications
Procedure
Lead sponsor
University of Rochester
Other
Eligibility
Male only
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2007
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Oct 15, 2013 · Synced Sep 15, 2026, 2:25 AM EDT
Completed Phase 2 Interventional

Open Label Phase Two Study of Enzalutamide With Concurrent Administration of Radium Ra 223 Dichloride in Castration-Resistant (Hormone-Refractory) Prostate Cancer Subjects With Symptomatic Bone Metastasis

NCT02507570
View directory record Official record
Conditions
Prostate Carcinoma Metastatic to the Bone
Interventions
Enzalutamide, Radium ra 223 dichloride
Drug · Radiation
Lead sponsor
Carolina Research Professionals, LLC
Other
Eligibility
18 Years and older · Male only
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
4
States / cities
Towson, Maryland • Syracuse, New York • Myrtle Beach, South Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 18, 2019 · Synced Sep 15, 2026, 2:25 AM EDT
Withdrawn Phase 2 Interventional

AMG 208 Tumor Microenvironment in Metastatic Castration Resistant Prostate Cancer (mCRPC)

NCT02420587
View directory record Official record
Conditions
Prostate Cancer
Interventions
AMG 208, Questionnaire
Drug · Behavioral
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older · Male only
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2014
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 19, 2015 · Synced Sep 15, 2026, 2:25 AM EDT
Completed Phase 3 Interventional Results available

Zoledronic Acid in Treating Patients With Metastatic Breast Cancer, Metastatic Prostate Cancer, or Multiple Myeloma With Bone Involvement

NCT00869206
View directory record Official record
Conditions
Breast Adenocarcinoma, DS Stage I Plasma Cell Myeloma, DS Stage II Plasma Cell Myeloma, Metastatic Malignant Neoplasm to the Bone, Pain, Musculoskeletal Complication, Urinary Complications
Interventions
zoledronic acid
Drug
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
1,822 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2017
U.S. locations
503
States / cities
Fairbanks, Alaska • Scottsdale, Arizona • Castro Valley, California + 353 more
Source: ClinicalTrials.gov public record
Updated Nov 6, 2018 · Synced Sep 15, 2026, 2:25 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional Results available

Testing the Safety of Different Doses of Olaparib Given Radium-223 for Men With Advanced Prostate Cancer With Bone Metastasis

NCT03317392
View directory record Official record
Conditions
Castration-Resistant Prostate Carcinoma, Metastatic Prostate Adenocarcinoma, Stage IVB Prostate Cancer AJCC v8
Interventions
Biopsy Procedure, Biospecimen Collection, Computed Tomography, Laboratory Biomarker Analysis, Magnetic Resonance Imaging, Olaparib, Quality-of-Life Assessment, Radium Ra 223 Dichloride
Procedure · Other · Drug + 1 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Male only
Enrollment
132 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
22
States / cities
La Jolla, California • Sacramento, California • New Haven, Connecticut + 17 more
Source: ClinicalTrials.gov public record
Updated Sep 8, 2026 · Synced Sep 15, 2026, 2:25 AM EDT
Completed Phase 2 Interventional Results available

Open Label Phase Two Trial of Radium Ra 223 Dichloride With Concurrent Administration of Abiraterone Acetate Plus Prednisone in Symptomatic Castration-Resistant (Hormone-Refractory) Prostate Cancer Subjects With Bone Metastasis

NCT02097303
View directory record Official record
Conditions
Prostate Cancer
Interventions
Concurrent use of Radium Ra 223 dichloride and Abiraterone Acetate plus Prednisone
Drug
Lead sponsor
Carolina Research Professionals, LLC
Other
Eligibility
18 Years and older · Male only
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
5
States / cities
Towson, Maryland • Omaha, Nebraska • Syracuse, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Jan 31, 2018 · Synced Sep 15, 2026, 2:25 AM EDT
Completed Not applicable Interventional Results available

ExAblate (MRgFUS) Treatment of Metastatic Bone Tumors for the Palliation of Pain

NCT00656305
View directory record Official record
Conditions
Bone Metastases, Multiple Myeloma
Interventions
ExAblate MRfFUS, Sham
Device
Lead sponsor
InSightec
Industry
Eligibility
18 Years to 100 Years
Enrollment
147 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
8
States / cities
La Jolla, California • Stanford, California • Boca Raton, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Feb 4, 2020 · Synced Sep 15, 2026, 2:25 AM EDT
Terminated Phase 2 Interventional

Doxorubicin and Strontium-89 With or Without Celecoxib in Treating Patients With Progressive Androgen-Independent Prostate Cancer and Bone Metastases

NCT00080782
View directory record Official record
Conditions
Metastatic Cancer, Prostate Cancer
Interventions
Celecoxib, Doxorubicin Hydrochloride, Strontium chloride Sr 89
Drug · Radiation
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
Male only
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2005
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 30, 2018 · Synced Sep 15, 2026, 2:25 AM EDT
Terminated Phase 2 Interventional

Ketoconazole With or Without Alendronate Sodium in Treating Patients With Metastatic Prostate Cancer

NCT00019695
View directory record Official record
Conditions
Stage IV Prostate Cancer, Bone Metastases, Adenocarcinoma of the Prostate, Recurrent Prostate Cancer
Interventions
alendronate sodium, ketoconazole
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Male only
Timeline
1999 – 2005
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 3, 2024 · Synced Sep 15, 2026, 2:25 AM EDT
Completed Phase 1 Interventional

Phase I Trial of Fixed Dose STI571 (Imatinib Mesylate) With Escalating Doses of Docetaxel in Patients With Metastatic Androgen-Independent Prostate Cancer

NCT00038194
View directory record Official record
Conditions
Prostate Cancer
Interventions
imatinib mesylate, docetaxel
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
Male only
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2005
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 30, 2018 · Synced Sep 15, 2026, 2:25 AM EDT
Terminated Phase 2 Interventional Results available

Trial of Cabozantinib (XL184) in Castrate-Resistant Prostate Cancer Metastatic to Bone

NCT01428219
View directory record Official record
Conditions
Prostate Cancer Metastatic
Interventions
Cabozantinib
Drug
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Eligibility
18 Years and older · Male only
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Dec 11, 2017 · Synced Sep 15, 2026, 2:25 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional Results available

Avelumab, Utomilumab, Anti-OX40 Antibody PF-04518600, and Radiation Therapy in Treating Patients With Advanced Malignancies

NCT03217747
View directory record Official record
Conditions
Advanced Malignant Solid Neoplasm, Castration-Resistant Prostate Carcinoma, Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm, Metastatic Prostate Carcinoma, Prostate Carcinoma Metastatic in the Bone, Refractory Malignant Solid Neoplasm, Stage IV Prostate Cancer AJCC v8, Stage IVA Prostate Cancer AJCC v8, Stage IVB Prostate Cancer AJCC v8
Interventions
Avelumab, Ivuxolimab, Radiation Therapy, Utomilumab
Drug · Biological · Radiation
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
173 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2026
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 4, 2026 · Synced Sep 15, 2026, 2:25 AM EDT
Completed Phase 3 Interventional Results available

Radium-223 Dichloride and Abiraterone Acetate Compared to Placebo and Abiraterone Acetate for Men With Cancer of the Prostate When Medical or Surgical Castration Does Not Work and When the Cancer Has Spread to the Bone, Has Not Been Treated With Chemotherapy and is Causing no or Only Mild Symptoms

NCT02043678
View directory record Official record
Conditions
Prostatic Neoplasms
Interventions
Radium-223 dichloride (Xofigo, BAY88-8223), Matching placebo (normal saline), Abiraterone, Prednisone/Prednisolone
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older · Male only
Enrollment
806 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2024
U.S. locations
29
States / cities
Anchorage, Alaska • Tucson, Arizona • Oceanside, California + 25 more
Source: ClinicalTrials.gov public record
Updated Feb 18, 2025 · Synced Sep 15, 2026, 2:25 AM EDT
Terminated Not applicable Interventional Results available

ExAblate Conformal Bone System Treatment of Metastatic Bone Tumors for the Palliation of Pain

NCT00981578
View directory record Official record
Conditions
Bone Metastases
Interventions
ExAblate 2100
Device
Lead sponsor
InSightec
Industry
Eligibility
18 Years and older
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2016
U.S. locations
5
States / cities
Duarte, California • San Francisco, California • Stanford, California + 2 more
Source: ClinicalTrials.gov public record
Updated Mar 10, 2020 · Synced Sep 15, 2026, 2:25 AM EDT
Terminated Phase 2 Interventional Results available

NaF Positron Emission Tomography/Computed Tomography (PET/CT)Imaging to Assess Treatment Responsiveness to TAK-700 in Patients With Castrate Resistant Prostate Cancer (CRPC) With Bone Metastasis

NCT01816048
View directory record Official record
Conditions
Prostatic Neoplasms, Prostate Cancer
Interventions
TAK-700, Fluorine F 18 Sodium Fluoride, Positron Emission Tomography, Computed Tomography
Drug · Radiation · Procedure
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years and older · Male only
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Dec 8, 2019 · Synced Sep 15, 2026, 2:25 AM EDT
Completed Phase 2 Interventional

Docetaxel With or Without Imatinib Mesylate in Treating Patients With Androgen-Independent Prostate Cancer and Bone Metastases

NCT00080678
View directory record Official record
Conditions
Metastatic Cancer, Prostate Cancer
Interventions
Docetaxel, Imatinib Mesylate
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
Male only
Enrollment
116 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2008
U.S. locations
3
States / cities
Boston, Massachusetts • New York, New York • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 11, 2012 · Synced Sep 15, 2026, 2:25 AM EDT
Terminated Phase 1 Interventional

Cohorts of Docetaxel or Cabazitaxel in Combination With the Potent CYP3A4 Inhibitor, Clarithromycin

NCT03043989
View directory record Official record
Conditions
Prostate Cancer
Interventions
Docetaxel, Cabazitaxel, Clarithromycin
Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older · Male only
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 16, 2020 · Synced Sep 15, 2026, 2:25 AM EDT
Completed Phase 2 Interventional

BMS-275291 in Treating Patients With Prostate Cancer That Has Not Responded to Hormone Therapy

NCT00040755
View directory record Official record
Conditions
Adenocarcinoma of the Prostate, Bone Metastases, Hormone-resistant Prostate Cancer, Recurrent Prostate Cancer, Stage IV Prostate Cancer
Interventions
rebimastat, laboratory biomarker analysis
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
Male only
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2002
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Jan 31, 2013 · Synced Sep 15, 2026, 2:25 AM EDT
Terminated Early Phase 1 Interventional

Cyclophosphamide and Cryoablation in Treating Patients With Advanced or Metastatic Epithelial Cancer

NCT00499733
View directory record Official record
Conditions
Cancer
Interventions
cyclophosphamide, Cryoablation
Drug · Device
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years to 120 Years
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2013
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 17, 2019 · Synced Sep 15, 2026, 2:25 AM EDT